With our free networking sessions, you can air common challenges of working in our sector and learn from others’ experiences. You are welcome to attend!
What we offer
- Highly interactive sessions, in a safe environment to share issues, challenges and learning
- Peer to peer advice
- Tools and tips from expert facilitator(s)
Who should attend?
Benefits
- Gain confidence to apply best practice, skills and processes in projects
- Pick up tips from those with more experience
- Build your professional network
Logistics and Costs
- 1-hour virtual session
- Free of charge (booking required)
- 8 – 16 participants
Obtaining Strategic Fit for a Study Idea
Coming soon!
When developing and commercializing a pharmaceutical product, new study ideas need to be clearly evaluated for Strategic Fit to ensure they reflect the overall strategy for the product.
This includes considering the study feasibility, availability of budget and how the results will enhance the commercialization and further development of the product.
This kind of evaluation should apply to all study ideas from the start of the development cycle, even those entering the laboratory phase, and as the product moves through its life cycle, strategic fit should be modified to address data gaps identified through continuous assessment of the needs of the product.
Moderators
Mauro Placchi
Clinical Development Consultant with over 30 years of experience in major pharmaceutical/biotech companies. Skilled in all aspects of clinical development programs in clinical and non-clinical, Investigator and Company-sponsored studies with innovative drugs, biologics, and devices.
Dr Richard Phillips MBBS DPM MBA
Richard qualified in medicine at St Mary's Hospital Medical School, now Imperial College in London. After several posts in the NHS, he joined Pfizer as a medical advisor responsible for rheumatology and infection. After obtaining an MBA from Kingston Business School, he set up the Outcomes Research Group at Pfizer. In 1999, he founded the Goffin Consultancy to provide evidence-based health economics and data review for the healthcare industry. With over 30 years' experience in the pharmaceutical industry, his clients have ranged from start-ups to blue chip pharmaceutical companies as well as OTC companies, medical device companies and private equity houses wanting to review potential investment opportunities.